Becton, Dickinson and Company $BDX Shares Bought by Running Oak Capital LLC

Running Oak Capital LLC lifted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 33.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 90,570 shares of the medical instruments supplier’s stock after purchasing an additional 22,683 shares during the quarter. Running Oak Capital LLC’s holdings in Becton, Dickinson and Company were worth $15,601,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in BDX. Saudi Central Bank purchased a new position in Becton, Dickinson and Company in the first quarter valued at $26,000. Smallwood Wealth Investment Management LLC purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at about $27,000. Alpine Bank Wealth Management acquired a new position in Becton, Dickinson and Company in the 1st quarter worth about $29,000. Cornerstone Planning Group LLC boosted its position in Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 99 shares in the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in Becton, Dickinson and Company in the first quarter valued at approximately $31,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BDX has been the topic of a number of recent analyst reports. Wells Fargo & Company increased their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Saturday, September 27th. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Finally, Argus lifted their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and an average price target of $205.40.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the firm’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president directly owned 4,887 shares of the company’s stock, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,023 shares of company stock valued at $562,036. 0.36% of the stock is owned by company insiders.

Becton, Dickinson and Company Stock Performance

BDX opened at $193.67 on Monday. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The firm has a market capitalization of $55.51 billion, a PE ratio of 34.83, a PEG ratio of 1.51 and a beta of 0.25. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The firm’s 50-day moving average price is $189.03 and its 200 day moving average price is $187.06.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts’ consensus estimates of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Becton, Dickinson and Company’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were issued a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.1%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is presently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.